Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BEKYREE vs NICOLAR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
BEKYREE (balcinrenone) is a selective mineralocorticoid receptor antagonist that binds to the mineralocorticoid receptor, inhibiting aldosterone-mediated sodium reabsorption and reducing inflammation and fibrosis in the kidney and heart.
Niacin (nicotinic acid) reduces hepatic production of VLDL and LDL by inhibiting diacylglycerol acyltransferase-2 (DGAT2) and decreasing free fatty acid mobilization from adipose tissue via activation of GPR109A (HM74A) receptor, leading to reduced triglyceride and LDL cholesterol synthesis. It also raises HDL cholesterol by decreasing hepatic clearance of apo A-I.
Treatment of chronic kidney disease in patients with type 2 diabetes,Reduction of albuminuria in chronic kidney disease
Treatment of primary hyperlipidemia and mixed dyslipidemia (Fredrickson Types IIa and IIb),Reduction of risk of recurrent myocardial infarction in patients with prior MI and hyperlipidemia,Regression of coronary atherosclerosis (with bile acid sequestrant),Adjunct to diet in patients with elevated triglycerides (Types IV and V)
1 mg/kg intravenously every 4 weeks; maximum dose 100 mg.
NICOLAR (niacin extended-release) is typically initiated at 500 mg orally once daily at bedtime, after a low-fat snack. The dose is increased by 500 mg every 4 weeks as tolerated, up to a maximum of 2000 mg once daily.
Terminal elimination half-life: 12 hours (range 10-14 h); prolonged in renal impairment (up to 30 h in Cr Cl <30 m L/min)
Terminal elimination half-life is 14-24 hours in adults with normal renal function; clinically, this supports twice-daily dosing. In moderate renal impairment (Cr Cl 30-59 m L/min), half-life extends to 24-36 hours, requiring dose adjustment.
Primarily metabolized by CYP3A4; minor contributions from CYP2C8 and CYP2C9.
Extensively metabolized in the liver via two pathways: conjugation with glycine (major) to form nicotinuric acid, and N-methylation to N-methylnicotinamide. Also undergoes oxidation to nicotinamide N-oxide. CYP2E1 may be involved in some metabolic steps.
Renal: 70% (unchanged drug), Biliary/fecal: 30% (metabolites and unchanged drug)
Primarily renal (60-70% as unchanged drug and metabolites), with 10-20% biliary/fecal. Hepatic metabolism to inactive metabolites accounts for ~30% of elimination.
95% bound to albumin and alpha-1-acid glycoprotein
Approximately 90% bound to human serum albumin, primarily to albumin and to a lesser extent to alpha-1-acid glycoprotein.
0.8-1.2 L/kg (indicates extensive tissue distribution)
Volume of distribution is 1.5-2.5 L/kg, indicating extensive tissue distribution and high extravascular penetration, particularly into the respiratory tract.
Oral: 60% (range 50-70%; first-pass metabolism reduces bioavailability)
Oral: 30-60% due to first-pass metabolism. Inhaled: 10-20% reaching systemic circulation (majority acts locally with high lung deposition).
No dose adjustment required for mild to moderate renal impairment (e GFR ≥30 m L/min/1.73 m²). Not recommended for severe renal impairment (e GFR <30 m L/min/1.73 m²) due to lack of data.
For patients with GFR <30 m L/min, reduce maximum dose to 1000 mg once daily due to increased risk of toxicity. For GFR 30-60 m L/min, no dose adjustment is required but monitor closely. No specific guidelines for dialysis.
Child-Pugh A: no adjustment; Child-Pugh B: 0.5 mg/kg intravenously every 4 weeks; Child-Pugh C: not recommended.
Contraindicated in patients with Child-Pugh class B or C cirrhosis. For Child-Pugh class A (mild impairment), initiate at 500 mg once daily and titrate cautiously, with maximum dose not exceeding 1000 mg once daily. Monitor liver function tests frequently.
Safety and efficacy not established in pediatric patients under 18 years.
Not approved for use in pediatric patients below 16 years of age for dyslipidemia. Safety and efficacy have not been established.
No specific dose adjustment required; consider age-related renal function and comorbidities.
No specific dose adjustment is recommended solely based on age. However, elderly patients may have reduced renal function and increased risk of adverse effects (e.g., flushing, hyperglycemia). Initiate at the lowest starting dose (500 mg once daily) and titrate slowly. Monitor renal function and metabolic parameters closely.
None.
Severe hepatotoxicity, including fulminant hepatic necrosis, has occurred with sustained-release formulations. Do not substitute for equivalent doses of immediate-release niacin.
Hyperkalemia: Monitor serum potassium regularly; avoid use with strong CYP3A4 inhibitors or potassium supplements.,Acute kidney injury: May occur; assess renal function before initiation.,Adrenal insufficiency: Not studied in patients with adrenal disorders.,Pregnancy: Limited data; avoid use unless benefit outweighs risk.
Hepatotoxicity: Monitor liver function tests; discontinue if persistent elevations or signs of hepatic injury.,Hyperuricemia and gout: May increase uric acid levels; use with caution in patients predisposed to gout.,Peptic ulcer: Niacin may reactivate or exacerbate peptic ulcer disease.,Facial flushing (prostaglandin-mediated): To reduce, take with aspirin 30 minutes prior, or use extended-release formulations.,Increased bleeding risk when used with anticoagulants.,Monitor glucose levels in diabetic patients; niacin may impair glucose tolerance.
Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin),Serum potassium >5.0 m Eq/L at initiation,e GFR <15 m L/min/1.73 m² (not studied),Hypersensitivity to balcinrenone or any excipient
Active liver disease or unexplained persistent transaminase elevations,Active peptic ulcer disease,Arterial bleeding,Hypersensitivity to niacin or any component,Lactation (relative contraindication)
No known food interactions. Avoid grapefruit juice if patient is on concurrent CYP3A4 substrates (though bevacizumab is not metabolized by CYP enzymes). Maintain adequate hydration to reduce risk of constipation, a common side effect.
Avoid high-fat meals with the dose, as they may increase the risk of flushing. Alcohol and hot beverages should be avoided close to dosing, as they can exacerbate flushing. Grapefruit juice has no significant interaction. Maintain a consistent diet to avoid fluctuations in blood glucose.
First trimester: Avoid use due to potential teratogenicity (limited human data, animal studies show risk). Second/Third trimester: Use only if benefit outweighs risk; monitor for fetal growth restriction and oligohydramnios.
NICOLAR (niacin) is classified as FDA Pregnancy Category C. Adverse effects have been observed in animal reproduction studies, but no adequate human studies exist. First trimester: potential risk based on animal data; use only if benefit outweighs risk. Second and third trimesters: no known specific risks but limited data; avoid high doses due to possible maternal hepatotoxicity and hyperglycemia.
No human data on excretion in breast milk. M/P ratio unknown. Avoid breastfeeding due to potential for adverse effects in nursing infant.
Niacin is excreted into breast milk; M/P ratio not reported. Concentrations are low but caution is advised due to potential for high doses to cause adverse effects in the infant. Monitor infant for flushing, GI upset, or hepatotoxicity.
No specific dose adjustments recommended based on pharmacokinetic changes. However, monitor therapeutic effect and adjust dose as needed based on clinical response and tolerability.
No specific dose adjustments are recommended for pregnancy; however, due to increased plasma volume and clearance, therapeutic efficacy may require monitoring. Use the lowest effective dose and monitor clinical response. Avoid extended-release formulations due to higher hepatotoxicity risk.
BEKYREE (bevacizumab-awwb) is a biosimilar to bevacizumab. Monitor for hypertension, proteinuria, and bleeding. Discontinue 28 days prior to elective surgery. Avoid use in patients with recent hemoptysis or serious hemorrhage. Infusion reactions may occur; premedicate with antihistamines and acetaminophen as per protocol.
NICOLAR is a brand name for niacin (nicotinic acid) extended-release. Doses should be taken at bedtime with a low-fat snack to reduce flushing. Avoid concomitant use with statins due to increased risk of myopathy. Monitor liver function tests and blood glucose regularly. Aspirin 325 mg taken 30 minutes prior can mitigate flushing.
Tell your doctor if you have a history of bleeding problems, blood clots, or recent surgery.,Avoid taking aspirin or NSAIDs unless prescribed by your doctor, as they increase bleeding risk.,Report any unusual bleeding, coughing up blood, or black/tarry stools immediately.,Women of childbearing age must use effective contraception during therapy and for 6 months after last dose.,Do not breastfeed during treatment and for 6 months after the last dose.,Monitor for signs of hypertension (severe headache, blurred vision) and proteinuria (foamy urine).
Take this medication at bedtime with a low-fat snack to help reduce flushing and stomach upset.,Flushing, warmth, or tingling may occur, especially after starting or increasing the dose; taking aspirin 30 minutes before the dose can help.,Avoid alcohol and hot beverages near the time you take this medication as they can worsen flushing.,Report any unexplained muscle pain, tenderness, or weakness to your doctor, especially if accompanied by fever or malaise.,Regular blood tests to monitor liver function and blood sugar are necessary while on this medication.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BEKYREE vs NICOLAR, answered by our medical review team.
BEKYREE is a Antilipemic Agent that works by BEKYREE (balcinrenone) is a selective mineralocorticoid receptor antagonist that binds to the mineralocorticoid receptor, inhibiting aldosterone-mediated sodium reabsorption and reducing inflammation and fibrosis in the kidney and heart.. NICOLAR is a Antilipemic agent that works by Niacin (nicotinic acid) reduces hepatic production of VLDL and LDL by inhibiting diacylglycerol acyltransferase-2 (DGAT2) and decreasing free fatty acid mobilization from adipose tissue via activation of GPR109A (HM74A) receptor, leading to reduced triglyceride and LDL cholesterol synthesis. It also raises HDL cholesterol by decreasing hepatic clearance of apo A-I.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BEKYREE and NICOLAR depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BEKYREE is: 1 mg/kg intravenously every 4 weeks; maximum dose 100 mg.. The standard adult dose of NICOLAR is: NICOLAR (niacin extended-release) is typically initiated at 500 mg orally once daily at bedtime, after a low-fat snack. The dose is increased by 500 mg every 4 weeks as tolerated, up to a maximum of 2000 mg once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BEKYREE and NICOLAR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BEKYREE is classified as Category C. First trimester: Avoid use due to potential teratogenicity (limited human data, animal studies show risk). Second/Third trimester: Use only if benefit outweighs risk; monitor for f. NICOLAR is classified as Category C. NICOLAR (niacin) is classified as FDA Pregnancy Category C. Adverse effects have been observed in animal reproduction studies, but no adequate human studies exist. First trimester:. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.